readthroughSign in
Jul 17, 2026Weekly roundup7 fact check notes

BMS trials post results across lung cancer, sarcoma, myelofibrosis; new stroke study opens

The week's registry activity for Bristol-Myers Squibb centered on results postings for completed and terminated studies, alongside one newly posted recruiting trial.

The week's registry activity for Bristol-Myers Squibb centered on results postings for completed and terminated studies, alongside one newly posted recruiting trial.

  • JAKARTA2 (NCT01523171), a Phase 2 trial of SAR302503 (fedratinib) in myelofibrosis patients previously treated with ruxolitinib, is listed with Bristol-Myers Squibb as lead sponsor.1 The trial's overall status is terminated, and results were first posted July 16, 2026. Enrollment reached 97 participants (actual).1
  • STILE (NCT03383302), a Phase 2 trial combining nivolumab with stereotactic body radiotherapy in early stage non-small cell lung cancer, is sponsored by Royal Marsden NHS Foundation Trust with Bristol-Myers Squibb as a collaborator.2
  • A Phase 2 study of rucaparib and nivolumab in leiomyosarcoma (NCT04624178) is sponsored by Memorial Sloan Kettering Cancer Center, with Bristol-Myers Squibb and Clovis Oncology, Inc. as collaborators.3
  • GLORY (NCT07711483), a Phase 2 study of glofitamab/gemcitabine/oxaliplatin bridging to lisocabtagene maraleucel in relapsed/refractory large B-cell lymphomas, is sponsored by Massachusetts General Hospital with Bristol-Myers Squibb as a collaborator4 that is supporting this research study by providing funding for the clinical trial activities.4 The study is not yet recruiting, first posted July 17, 2026, with planned enrollment of 56 participants (estimated).4
  • STIPS (NCT07704840), a Phase 2 pilot trial of BMS-986368, a FAAH/MAGL inhibitor, for post-stroke spasticity, is sponsored by Alberto Esquenazi with Bristol-Myers Squibb as a collaborator.5 The study is recruiting, first posted July 15, 2026, with planned enrollment of 42 participants (estimated).5

Fact check notes

  • ImpreciseSpanning a lead-sponsored terminated trial and four externally sponsored studies where BMS supplies drug or fundingOnly the GLORY entry explicitly states BMS funding; for STILE, the rucaparib/nivolumab trial, and STIPS, BMS's role as drug supplier/funder is inferred from being listed as a collaborator rather than explicitly stated in the source.
  • ImpreciseSTILE (NCT03383302) is a Phase 2 trial combining nivolumab with SBRT in early stage NSCLC, sponsored by Royal Marsden with BMS as collaborator, completed, results first posted July 17, 2026, planned enrollment of 31 patientsThe trial is listed as combined Phase 1/Phase 2, not solely Phase 2. Also, while 31 was the planned enrollment, actual enrollment reached 36 participants, which the entry does not mention, potentially understating the trial's size.
  • Checker's noteThe summary claims all five records were 'updated between July 15 and 17, 2026,' but STIPS's last update posted date is 2026-07-29, outside that range.
  • Checker's noteSTILE is listed in the source as a combined Phase 1/Phase 2 trial, but the entry describes it only as 'Phase 2.'
  • Checker's noteThe STILE entry cites only the planned enrollment of 31 patients without noting the actual enrollment of 36 participants recorded in the source.
  • Sentence removedThe study is completed, with results first posted July 17, 2026, and planned enrollment of 31 patients.a figure with no citation
  • Sentence removedThe trial is active, not recruiting, with results first posted July 17, 2026, and actual enrollment of 20 participants.a figure with no citation

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.